Skip to main content

The RheumNow Week in Review – 27 January 2017

Jan 27, 2017 4:13 pm

Dr. Cush reviews highlights from the past week on

  1. CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA  (NOTE: video error says tocilizumab, when tofacitinib (Xeljanz) was intended!)

  2. Janssen has applied to FDA for new indications (AS, PsA) for golimumab based on GO-ALIVE, GO-VIBRANT trials

  3. FDA has granted priority review designation for use of tocilizumab in giant cell artertitis based on GiACTA study

  4. Canada to consider sticker warnings that "opioid painkillers can cause addiction and overdose"

  5. Bronchiectasis Rheumatoid overlap syndrome (BROS): Study of 147 patients shows RA an independent risk factor for mortality in pts with bronchiectasis

  6. Provacative ARD letter states Renal Bx should be done whenever treatment strategies depend on renal involvement

  7. RAPID3 shows strong correlations w/ BASDAI (r=0.84) & ASDAS (r=0.74) in Axial SpA pts (similar to BASDAI)

  8. Among 103 SLE pts ~10% had "Rhupus" polyarthritis; they had less renal, but more joints, erosions, hi ESR/CRP levels

  9. Study of 565k people shows chronic PPI has a nearly 2 fold risk of C. dificile & 4 fold risk of campylobacter infxn

  10. Complement Driven Vasculopathy Underlies Neuropsychiatric Lupus 

  11. C5a and Neutrophils as Early Mediators in Inflammatory Arthritis.

  12. FDA Issues Draft Guidance on Biosimilar Interchangeability 

  13. The Challenge of Screening for Obstructive Sleep Apnea 


The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.